References: 1. Kovaltry Product Monograph, Bayer Inc., May 30, 2024. 2. Data on file 9, Bayer Inc., March 31, 2021. 3. Shah A, et al. Pharmacokinetic properties of BAY 81-8973, Bayer’s full-length recombinant factor VIII product. Haemophilia 2015;1–6. 4. Kavakli K, et al. Prophylaxis vs. on-demand treatment with BAY 81-8973, a full-length plasma protein-free recombinant factor VIII product: results from a randomized trial (LEOPOLD II). J Thromb Haemost 2015;13:360–9. 5. Ljung R, et al. BAY 81-8973 safety and efficacy for prophylaxis and treatment of bleeds in previously treated children with severe haemophilia A: results of the LEOPOLD Kids Trial. Haemophilia 2016;22(3):354–60. 6. World Federation of Hemophilia. Guidelines for the management of hemophilia. 2^nd edition. Blackwell Publishing Ltd., 2012. 7. Iorio A, et al. Estimating and interpreting the pharmacokinetic profiles of individual patients with hemophilia A or B using a population pharmacokinetic approach: communication from the SSC of the ISTH. J Thromb Haemost 2017;15:2461–5. 8. Association of Hemophilia Clinic Directors of Canada (AHCDC), 2018. 9. Eloctate^® Product Monograph, sanofi-aventis Canada Inc., September 25, 2020. 10. Nuwiq^® Product Monograph, Octapharma Canada Inc., December 14, 2018. 11. Canadian Blood Services, Customer Letter, October 31, 2017.